A. Davie, “Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy”, Grhta, vol. 10, no. 1, pp. 62–69, Sep. 2023.